



## Media Release

18 June 2010

---

### PHARMAXIS CHIEF EXECUTIVE OFFICER

---

The Chairman of the Pharmaxis Ltd Board, Mr Denis Hanley advises that the company's Chief Executive Officer Dr Alan Robertson has undergone a medical procedure. Dr Robertson is expected to make a full recovery but will be absent from the office for the next few weeks. During this time Dr Robertson's duties will be handled by other members of the senior management team led by its Chief Operating Officer, Gary Phillips, and its Chief Financial Officer, David McGarvey.

The Pharmaxis Board and staff wish Dr Robertson a speedy recovery and look forward to his return to work.

#ENDS#

**SOURCE:** Pharmaxis Ltd, Sydney, Australia

**CONTACT:** David McGarvey – Company Secretary

Ph: +61 2 9454 7200 or email [david.mcgarvey@pharmaxis.com.au](mailto:david.mcgarvey@pharmaxis.com.au)

**RELEASED THROUGH:**

**Australia:**

Felicity Moffatt, phone +61 418 677 701 or email [felicity.moffatt@pharmaxis.com.au](mailto:felicity.moffatt@pharmaxis.com.au)

**About Pharmaxis**

Pharmaxis (ACN 082 811 630) is a specialist pharmaceutical company involved in the research, development and commercialization of therapeutic products for chronic respiratory and immune disorders. Its development pipeline of products includes Aridol for the management of asthma, Bronchitol for cystic fibrosis, bronchiectasis and chronic obstructive pulmonary disease (COPD), PXS25 for the treatment of lung fibrosis and PXS4159 for asthma.

Founded in 1998, Pharmaxis is listed on the Australian Securities Exchange (symbol PXS). The company is headquartered in Sydney at its TGA-approved manufacturing facilities. For more information about Pharmaxis, go to [www.pharmaxis.com.au](http://www.pharmaxis.com.au) or contact Investor Relations on phone +61 2 9454 7200.

**Forward-Looking Statements**

Forward-looking statements in this media release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the potential for Aridol and/or Bronchitol. All forward-looking statements included in this media release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. We cannot guarantee that any product candidate will receive regulatory approval or that we will seek any such approval. Factors that could cause or contribute to such differences include, but are not limited to, factors discussed in the "Risk Factors" section of our Statutory Annual Report available on the Pharmaxis website.